Smartphone Quit App Tested in Queensland Pregnancy Trial

Pregnancy is a powerful window for behaviour change, and giving up smoking is one of the most important gifts an expectant mother can offer her baby. In Australia, around one in ten women still smoke during the first half of pregnancy, with rates climbing above 30 per cent in some remote and Aboriginal and Torres Strait Islander communities. The persistence of these figures has pushed researchers across Queensland to look for scalable, low-cost interventions that fit into busy antenatal schedules.

Mobile health tools, often called mHealth, have exploded in popularity over the past decade. Smartphones are now almost universal among Australian adults, including those on lower incomes, which makes them a promising channel for health messaging that can be tailored, automated, and available 24 hours a day. Pregnancy adds an extra layer of motivation, and clinicians have long hoped that the right digital nudge could help translate that motivation into lasting abstinence.

A recent pilot randomised trial set out to test that hope directly. Researchers compared a purpose-built smartphone app against usual care among pregnant women who smoke, measuring quit rates, app engagement, and participant satisfaction. The study was small but rigorous, and its findings are now feeding into larger trials being considered across several Australian maternity services.

For a translational collaborative working at the intersection of research and clinical practice, this kind of work sits at the heart of its mission. Turning research discoveries into routine clinical care means designing studies with the realities of local health services in mind, from the logistics of antenatal appointments at the Royal Brisbane and Women's Hospital to the patchy connectivity experienced in the Darling Downs. The Queensland smoking-in-pregnancy story is therefore both a public health priority and a practical test bed for digital innovation.

Smoking During Pregnancy in the Australian Context

Tobacco use in pregnancy remains a leading preventable cause of low birthweight, preterm birth, and sudden infant death. National data show that roughly 9.7 per cent of mothers smoked at some point during pregnancy in 2022, with much higher rates among women in regional Queensland and among Aboriginal and Torres Strait Islander mothers. The burden falls hardest on communities that already face barriers to antenatal care.

Cost-of-living pressures add another dimension. With cigarettes now priced above forty dollars a pack in Australia, household budgets are stretched thin, and many expectant mothers describe a daily tension between the cost of nicotine and the cost of groceries. Behavioural support programs, including the national Quitline phone counselling service, have helped many women quit, but reach remains uneven.

There is also a stubborn cultural layer. Smoking during pregnancy is sometimes normalised in social networks where many peers smoke, and stigma can drive women to hide their habit from clinicians. Digital tools can offer a discreet channel, allowing women to access support without sitting in a waiting room and being overheard. That privacy angle matters in tight-knit rural communities where word travels fast.

How the Pilot Trial Was Structured

The trial recruited pregnant women who smoked at least one cigarette a day from antenatal clinics across south-east Queensland. Participants were randomly assigned to receive either usual antenatal care plus brief cessation advice, or usual care plus access to the smartphone app throughout their pregnancy. The team tracked self-reported abstinence and, where possible, confirmed quitting with exhaled carbon monoxide readings taken at routine appointments.

Sample size calculations were designed to detect a clinically meaningful difference in continuous abstinence rather than to deliver definitive effectiveness data. As a pilot, the study focused on feasibility signals: how many women would enrol, how often they would open it, and whether the app would survive contact with the realities of clinical workflows. Recruitment opened through midwifery-led booking visits and continued across multiple gestation windows.

Randomisation was important because it balanced unknown influences such as partner smoking, mental health history, and socioeconomic circumstances between the two groups. Researchers collected qualitative feedback through short interviews, capturing the texture of participant experience that numbers alone cannot show. Concerns about representativeness are well known in Australian trials, and those who want a deeper dive can read more about trial diversity challenges in geographically dispersed populations.

The Smartphone App and What It Offered

The app combined several evidence-based behavioural techniques into a single daily experience. Users received tailored push notifications timed to their gestation, short cognitive tasks to ride out cravings, and tracking dashboards that visualised smoke-free days and money saved. Personalised feedback adapted as pregnancy progressed, and a library of videos featured Australian midwives and paediatricians explaining the benefits of quitting at each stage.

A standout feature was the in-app financial calculator that translated cigarettes avoided into grocery trolleys, petrol tank refills, and pram upgrades, framing the savings in ways that resonated with Australian household budgets. Another module offered scripts for conversations with partners or household members who smoked, recognising that quitting rarely happens in isolation. Gamified elements, including badges and milestone celebrations, aimed to keep engagement high during the long middle trimester when motivation often dips.

The design drew on the broader smoking cessation evidence base and was reviewed by consumer representatives from maternity consumer councils. Cultural safety advisors also reviewed content to ensure the language and imagery did not exclude Aboriginal and Torres Strait Islander women or those from culturally and linguistically diverse backgrounds.

What Participants Did and How They Felt

Adherence was strong by digital health standards. On average, participants opened the app more than four times a week across the first trimester, with usage tapering as pregnancy advanced. Women in the intervention arm consistently rated it above seven out of ten for usefulness, and many said the daily prompts felt like a friendly check-in rather than a lecture. The mid-pregnancy dip in engagement was real, but a redesigned milestone notification helped recover some lost ground.

Qualitative interviews surfaced themes that rarely appear in quantitative datasets. Several women described the app as a kind of quiet companion during moments when cravings hit late at night and no one else was awake. Others appreciated being able to revisit content at their own pace, free from the time pressures of a clinic visit. A small number of women in rural Queensland mentioned patchy mobile coverage as a frustration, underscoring that any digital tool needs offline functionality to be truly national.

Critically, no participants raised serious privacy concerns, even though the app collected detailed behavioural data. That acceptance reflects a growing familiarity with health apps, but researchers caution that trust should never be taken for granted and that transparent data handling remains essential.

Quit Rates and What the Numbers Show

The intervention group recorded higher continuous abstinence rates at the end of pregnancy compared with usual care, though the absolute numbers were modest given the pilot sample size. Biochemically validated quit rates, measured through exhaled carbon monoxide, told a similar story, suggesting that self-report was not dramatically overstating success. Birth outcomes, including mean birthweight and gestational age at delivery, trended in a favourable direction but were not powered to reach statistical significance.

These figures sit within a wider literature showing that digital cessation tools can produce small but meaningful gains when layered on top of standard care. The pilot's contribution is less about a single headline number and more about confirming that the design works, the recruitment pathway is feasible, and the outcome measures are sensitive enough to detect change. That confirmation is precisely what larger trials need before committing years of effort and substantial funding.

Ethical and Practical Considerations

Ethics approval covered data security, consent processes for ongoing data collection, and the handling of sensitive information about mental health and substance use. Researchers were careful to ensure women did not feel penalised for continued smoking, since antenatal care must remain a safe space regardless of quit attempts. The protocol also included pathways for participants who reported worsening mood or who flagged domestic violence concerns through app interactions.

Broader questions remain about the ethics of using real-world data in studies like this, particularly when apps collect rich behavioural traces that go well beyond what a traditional trial would capture. Australian researchers are increasingly expected to demonstrate strong governance around data linkage, storage, and secondary use, especially when working with vulnerable groups.

There are also equity questions. Smartphones are nearly universal in Australia, but data costs, battery access, and digital literacy still vary. A genuinely national rollout would need to address these gaps, possibly through partnerships with community health workers and Aboriginal Community Controlled Health Organisations.

What Comes Next

The next step is a fully powered multicentre trial across Queensland, New South Wales, and Western Australia, with recruitment embedded into public hospital antenatal services. If the larger trial confirms the pilot signal, the app could become a standard element of pregnancy cessation care, available free through antenatal clinics and downloadable with a clinician's code. Researchers are also exploring integrations with the national Quitline service and with electronic medical record platforms already used across Queensland Health.

Translation is rarely a straight line from study to clinic, but the infrastructure exists to make it happen. Partnerships between research institutes, universities, and health services are exactly what translational collaboratives like brisbanediamantina.com are built to support, bridging the gap between a promising pilot and a tool that ends up in the pocket of every pregnant woman who wants to quit.

Subscribe to updates from Brisbane Diamantina Health Partners to keep across translational research that is reshaping maternity, public health, and clinical innovation across Queensland, with the latest trial findings, funding opportunities, and partnership news delivered straight to your inbox.